Latest Content

The FDA confirmed phase 1 and nonclinical data support pediatric phase 2 development of IVMED-85, a non-atropine daily eye drop for myopia progression.

Bausch + Lomb’s EyeGility preloaded enVista IOL inserter streamlines cataract surgery with push-plunger delivery, less handling, and faster workflow.

Frantz EyeCare reported 98% of Light Adjustable Lens patients within ±0.50 D of target but omitted cohort, follow-up, and safety details.

i-Lumen Scientific randomly assigned its first US patient in the sham-controlled i-SIGHT2 pivotal study of its investigational, noninvasive bioelectric AMD device at Texas Retina Associates.

A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.

Jessica Steen, OD, FAAO, DipABO, stated that each ADC can have distinct ophthalmic monitoring needs and management protocols.

Lab-grown retinal endothelial cells from iPSCs rebuild mouse retinal vessels and power blood-retina barrier chips, accelerating diabetic retinopathy research and therapy discovery.

A disconnect between the signs and symptoms of OSD can easily lead to misdiagnosis or undertreatment if clinicians rely solely on a slit lamp observation.

University of Waterloo unveils chairside 3D-printed contacts, delivering custom-fit lenses in 20 minutes—potentially cutting weeks of trial fittings for irregular corneas.

Esen K. Akpek, MD, speaks with the Eye Care Network in recognition of Dry Eye Awareness Month.

A new pilot trial tests ZOC2017217 lanosterol-derived cataract eye drops, aiming to slow lens clouding and guide Phase 3 development amid mixed human evidence.

In this Q&A, LENZ CFO Dan Chevallard on Vizz's ECP momentum, telehealth expansion, and the global push to end reading glasses for presbyopia.

Antineoplastics were the most frequently implicated drug class in review